Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Debt Repayment

Cash used to repay borrowings during the period.

Viatris Inc.NASDAQ: VTRS

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment turns negative

Q2 FY2026 debt repayment was -$922.2M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was -$923.5M.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, down 25.2 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near -$922.2M or moves back toward the trailing-twelve-month quarterly average of -$230.88M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$922.2M— QoQ
Last fiscal yearDec 2025
$100K+100.0% YoY
LTMJun 2026
-$923.5M-68.3% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
100K USD
Year-over-year change
+100.0%

Debt Repayment vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -68.3% is the 5th highest of 10, against a peer median of -76.8%.
  • Debt repayment amounts to 6.3% of revenue for VTRS, versus a peer median of 3.8%.
VTRS Competitors
Debt Repayment for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹12.6B INR+932.0%—3.8%
ALKSAlkermes plcLTM Sep 2026$3.01B USD+1140.8%—171.8%
HLNHaleon plcFY2025£1.28B GBP-315.8%—11.6%
BHCBausch Health Companies Inc.LTM Jun 2026$1.01B USD-591.3%-13.7%9.3%
VTRSViatris Inc.LTM Jun 2026$923.5M USD-68.3%—6.3%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$475.36M USD-76.8%+9.8%2.7%
OGNOrganon & Co.LTM Sep 2026$214M USD-23.6%+61.9%3.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$146.75M USD+182.6%—4.7%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$12.19M USD-103.7%+50.2%1.3%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$1.63M USD-121.0%—0.2%
Peer median (excluding VTRS) —-76.8%+30.0%3.8%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
Deferred Income Tax675.7M(25.9M)(387.1M)(767.6M)(476.5M)
Stock-Based Compensation111.2M116.4M180.7M146.1M177.7M
Change in Working Capital(1.8B)(922.6M)(711.3M)(318.6M)(2.5B)
Accounts Receivables59.3M(240.3M)78.6M300.1M334.6M
Inventory(427.6M)(259.5M)(613.3M)(723.4M)(106.4M)
Accounts Payables(70.4M)170.2M314.7M36M(168M)
Other Working Capital(1.37B)(593M)(491.3M)68.7M(2.56B)
Other Non-Cash Items797.4M(1.28B)922.1M1.17B5.84B
Operating Cash Flow3.02B3B2.8B2.3B2.32B
Capital Expenditures(509.4M)(489.4M)(474.5M)(326M)(378.8M)
Acquisitions (Net)277M0(667.7M)(350M)0
Purchases of Investments(30.2M)(30.2M)(26.3M)(26M)(23.9M)
Sales of Investments29.8M29.9M26.3M26M23.9M
Other Investing Activities115M1.96B280.6M2.48B(48.9M)
Investing Cash Flow(117.8M)1.47B(764.1M)1.8B(427.7M)
Debt Repayment(2.1B)(3.28B)(1.25B)(3.71B)100K
Common Stock Issued03.3M3.1M2.5M2.6M
Common Stock Repurchased(17.4M)0(250M)(250M)(500.5M)
Dividends Paid(399M)(581.6M)(575.6M)(574.8M)(561.2M)
Other Financing Activities(496.5M)(19.5M)(229.8M)205.6M(234.9M)
Financing Cash Flow(3.01B)(3.88B)(2.3B)(4.33B)(1.29B)
Effect of Forex Changes(30.9M)(38.9M)(2.5M)(30.7M)17.6M
Net Change in Cash(143.8M)556.3M(268.9M)(257.5M)611.9M
Free Cash Flow2.51B2.51B2.33B1.98B1.94B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.